Efficacy and Safety of Valsartan, an Angiotensin II Receptor Antagonist, in Hypertension After Renal Transplantation: A Randomized Multicenter Study

Transplantation Proceedings

Volumn 38, Issue 8, 2006, Pages 2419-2423

  Andres A ^a   Morales, E ^a   Morales, J M ^a   Bosch, I ^b   Campo, C ^b   Ruilope, L M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Novartis Pharma   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HEMOGLOBIN; PLACEBO; POTASSIUM; VALSARTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANKLE EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION KINETICS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLACEBOS; POSTOPERATIVE COMPLICATIONS; SAFETY; SYSTOLE; TETRAZOLES; VALINE;

EID: 33750606854     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.066     Document Type: Article

References (33)

1. Raine A.E. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant 10 Suppl 1 (1995) 95
2. Ponticelli C., Montagnino G., Aroldi A., et al. Hypertension after renal transplantation. Am J Kidney Dis 21 Suppl 2 (1993) 73
3. First M., Neylan J., Rocher L., et al. Hypertension after renal transplantation. J Am Soc Nephrol 4 Suppl 8 (1994) S30
4. Luke R. Pathophysiology and treatment of post-transplant hypertension. J Am Soc Nephrol 2 Suppl 1 (1991) S37
5. Budde K., Waiser J., Fritsche L., et al. Hypertension in patients after renal transplantatio. Transplant Proc 29 (1997) 209
6. Malek-Hosseini S., Ghahramani N., Behzadi S., et al. Incidence of post-transplant hypertension among renal allograft recipients. Transplant Proc 30 (1998) 775
7. Koomans H.A., and Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 72 Suppl 6 (2001) S9
8. Geerlings W., Tufveson G., Ehrich J.H., et al. Report on the management al renal failure in Europe XXIII. Nephrol Dial Transplant 9 Suppl 1 (1994) 6
9. Aakhus S., Dahl K., and Wideroe T.E. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14 (1999) 648
10. Stigant C.E., Cohen J., Vivera M., et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 35 (2000) 58
11. Kasiske B.L. Cardiovascular disease after renal transplantation. Semin Nephrol 20 (2000) 170
12. Opelz G., Wujciak T., and Ritz E. Association of chronic Kidney graf failure with recipient blood pressure. Kidney Int 53 (1998) 217
13. Cosio F.G., Pelletier R.P., Sedmak D.D., et al. Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 56 (1999) 1912
14. Cosio F.G., Pelletier R.P., Pesavento T.E., et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 59 (2001) 1158
15. Oparil S., Dyke S., Harris F., et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Therap 18 (1996) 797
16. Benz J., Oshrain C., Henry D., et al. Valsartan a new Angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydroclorotiazide. J Clin Pharmacol 37 (1997) 101
17. Holgado R., Anaya F., and Del Castillo D. Angiotensin II type 1 (AT1) receptor antagonist in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 16 Suppl 1 (2001) 117
18. Del Castillo D., Campistol J.M., Guira del Castillo D., et al. Efficacy and Safety of Losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 68 (1998) 135
19. Kohlhaw K., Wonigeit K., Frei U., et al. Effect of the calcium channel blocker diltiazen on cyclosporine A blood levels and dose requirements. Transplant Proc 20 (1988) 572
20. Hricik D.E., Browning P.J., Kopelman R., et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis in a solitary kidney. N Engl J Med 308 (1983) 373
21. Denton M.D., Magee C.C., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 (1999) 1083
22. Matas A.J., Burke Jr. J.F., DeVault Jr. G.A., et al. Chronic rejection. J Am Soc Nephrol 4 Suppl 8 (1994) 523
23. Womer K.L., Vella J.P., and Sayegh M.H. Chronic allograft dysfunction; mechanisms and new approaches to therapy. Semin Nephrol 20 (2000) 126
24. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 145
25. Giatras I., Lau J., and Levey A. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomised trials. Ann Intern Med 127 (1997) 337
26. Brenner B., Cooper M.E., Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and Nephropathy. N Engl J Med 345 (2001) 861
27. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870
28. Campistol J.M., Inigo P., Jimenez W., et al. Losartan decreases plasma levels of TGF-□ in transplant patients with chronic allograft nephropathy. Kidney Int 56 (1999) 714
29. Stigant C.E., Cohen J., Vivera M., et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 35 (2000) 154
30. Montanaro D., Gropuzzo M., Tulissi P., et al. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplant Proc 37 (2005) 991
31. Artz M.A., Hilbrands L.B., Borm G., et al. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 19 (2004) 2852
32. Zaltzman J.S., Nash M., Chiu R., et al. Renin-angiotensin system blockade in biopsy-proven allograft nephropathy. Transplant Proc 35 (2003) 2415
33. Ramanathan V., Suki W.N., Rosen D., et al. Chronic allograft nephropathy and nephrotic range proteinuria. Clin Transplant 19 (2005) 413